Navigation

Asthma (in children) - corticosteroids: costing statement

A costing statement has been produced by NICE to provide an implementation tool to estimate the financial impact to the NHS of implementing the technology appraisal TA131, inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years.

The Institute would welcome feedback from users to inform the development of future templates. Please email your comments to costing@nice.org.uk

This page was last updated: 23 December 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.